Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
29.11
+0.54 (+1.91%)
Streaming Delayed Price
Updated: 1:07 PM EDT, Mar 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
Is SoundHound AI a Millionaire-Maker Stock?
↗
December 03, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
↗
November 15, 2024
Via
Benzinga
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
↗
November 06, 2024
The company also raised its outlook for the year.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
↗
October 29, 2024
Via
Benzinga
A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus
↗
October 23, 2024
Via
Benzinga
Teva to Present at the Jefferies London Healthcare Conference
November 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
↗
November 06, 2024
TEVA earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
↗
November 06, 2024
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.
Via
Benzinga
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
November 06, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
↗
November 01, 2024
Amid the election, and a Fed rate vote, earnings season roars ahead.
Via
Investor's Business Daily
Topics
Economy
Stocks
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
November 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
November 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Statement on European Commission Decision; Company to Appeal
October 31, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 22, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
↗
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
↗
October 11, 2024
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud...
Via
Benzinga
Topics
Fraud
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
↗
October 10, 2024
Via
Benzinga
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
↗
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
October 03, 2024
From
Teva Pharmaceutical Industries Ltd; mAbxience
Via
GlobeNewswire
Teva Launches Generic Version Of Sandostatin In The US
↗
October 01, 2024
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know.
Via
Benzinga
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
October 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
September 30, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
↗
September 30, 2024
Via
Benzinga
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
↗
September 30, 2024
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
